Professor Serge Gauthier
MD, FRCPC, Department of Neurology and Neurosurgery, Department of Psychiatry, Department of Medicine, McGill University and director of the Alzheimer Disease and Related Disorders Unit, McGill Centre for Studies in Aging, Verdun, Canada.
Professor Gauthier is also Associate Member, School of Physical and Occupational Therapy, McGill University; Associate Member, Institut Universitaire de Gériatrie, Universtity of Montreal; Member, Douglas Hospital Research Center; and Senior Scientist, Industry Programs Branch, Canadian Institutes of Health Research. For 30 years now, Professor Gauthier has lectured and published extensively on dementia and related topics.
Contributions to CNSforum by Professor Serge Gauthier:
Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons
Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder
Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial
Transient epileptic amnesia: regional brain atrophy and its relationship to memory deficits
Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial
Prodromal Alzheimer's disease: successive emergence of the clinical symptoms
Imaging amyloid deposition in Lewy body diseases
Vitamin B12 status and rate of brain volume loss in community-dwelling elderly
Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial
Long term effects of Aß42 immunisation in Alzheimer's disease: follow-up of a randomized, placebo-controlled phase I trial
High risk of cognitive and functional decline after postoperative delirium. A three-year prospective study
Safety and efficacy of galantamine in subjects with mild cognitive impairment
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial
Donepezil treatment of patients with severe Alzheimer’s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial
Conjugal Alzheimer disease: risk in children when both parents have Alzheimer disease
Imaging of amyloid beta in Alzheimer's disease with (18)F-BAY94-9172, a novel PET tracer: proof of mechanism
Dietary patterns and risk of dementia: The Three-City cohort study
Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study
Galantamine treatment of vascular dementia: a randomized trial
Donepezil preserves cognition and global function in patients with severe Alzheimer disease
Activities of daily living in frontotemporal dementia and Alzheimer disease
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study
Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial
Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study
Conversion from subtypes of mild cognitive impairment to Alzheimer dementia
Relation of higher folate intake to lower risk of Alzheimer disease in the elderly
Improvement of episodic memory in persons with mild cognitive impairment and healthy older adults: evidence from a cognitive intervention program
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease
Lewy bodies in the amygdala increase risk for major depression in subjects with Alzheimer disease
Restriction in complex activities of daily living in MCI: impact on outcome
Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD?
Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer’s disease
The characteristics of patients with uncertain/mild cognitive impairment on the Alzheimer Disease Assessment Scale-cognitive subscale
Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study
Inverse relationship between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans
Cognitive impairment in patients with idiopathic normal pressure hydrocephalus
Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life
Delusions and hallucinations are associated with worse outcomes in Alzheimer Disease.
Cerebral small-vessel disease and decline in information processing speed, executive function and memory
Reduced risk of Alzheimer’s disease with high folate intake: the Baltimore Longitudinal Study of Aging
APOE genotype, cholesterol level, lipid-lowering treatment, and dementia
Donepezil for dementia in Parkinson’s disease: a randomized, double blind, placebo controlled, crossover study
Atorvastatin for the treatment of mild to moderate Alzheimer disease
Nighttime insomnia treatment and education for Alzheimer’s disease: a randomized, controlled trial
The Montreal Cognitive Assessment, MOCA: a brief screening tool for Mild Cognitive Impairment
Accuracy of self-reported depression in persons with dementia
Distinctive clinical features of Mild Cognitive Impairment with subcortical cerebrovascular disease.
Motor signs during the course of Alzheimer disease.
Depressive symptoms increase the likelihood of cognitive impairment in elderly people with subclinical Alzheimer pathology.
Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease
Efficacy of donepezil in mild cognitive impairment
The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer’s disease.
Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomized double-blind trial.
Cholesterol and APOE genotype interact to influence Alzheimer disease progression
Effects of cholinergic drugs and cognitive training on dementia
How heritable is Alzheimer’s disease late in life? Findings from Swedish twins
Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil.
Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease
Rate of cognitive decline and mortality in Alzheimer’s disease.
An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trial.
Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD
Atrophy of the substantia innominata on Magnetic Resonance Imaging predicts response to donepezil treatment in Alzheimer’s disease patients.
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization
Five-year follow-up of cognitive impairment with no dementia
Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial.
Prospective study of alcohol consumption and risk of dementia in older adults
Memantine in moderate-to-severe Alzheimer’s disease
Impaired financial abilities in mild cognitive impairment
Survival study of vascular dementia in Rochester, Minnesota
Fluctuations in attention. PD dementia vs DLB with parkinsonism.
Diagnostic profile of young and middle-aged memory clinic patients
Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type.”
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months
Natural history of mild cognitive impairment in older persons.
The prevalence of frontotemporal dementia